Literature DB >> 18945418

Recommendations for cervical cancer prevention in Asia Pacific.

Suzanne M Garland1, Jack Cuzick, Efren J Domingo, Sue J Goldie, Young-Tak Kim, Ryo Konno, D Maxwell Parkin, You-Lin Qiao, Rengaswamy Sankaranarayanan, Peter L Stern, Sun Kuie Tay, F Xavier Bosch.   

Abstract

Asia Oceania includes countries from both the Asia Pacific region and Australasia, which cover very diverse geographical areas and populations as well as bearing 52% of the cervical cancer burden in the world. Human papillomavirus (HPV) genotype distribution in women with normal cytology varies between countries in this region, as well as with the distribution typically observed in worldwide estimates or in Western countries. HPV-16 remains the predominant oncogenic type for high-grade cervical dysplasia and cervical cancer across the region, and HPV-18 is generally among the five most common types. HPV-58 is commonly found in cervical cancer as well as in women with normal cytology, and HPV-31, 33 and 35 are relatively less frequent in these regions compared to the West. While screening programmes have been proposed and implemented in several populations, successful programmes are rather limited and the majority of countries still have no or minimal screening services. Prophylactic HPV vaccination will only be feasible when it becomes affordable, thus the current priority and the short-term goal for cervical cancer control is to identify feasible and effective screening measures, and to find the most effective way to combine vaccination with sustainable screening programmes. This Regional Report has carefully described the disease burden of HPV and cervical cancer and the current situations in cervical cancer prevention for many countries in the Asia Oceania region. These data identify the many challenges and opportunities to be considered for policy decisions for cervical cancer control. Furthermore, this report presents the results of advanced decision analytic models calibrated to countries in the region that provide early insight into what strategies are most promising and those likely to be cost-effective and affordable. It thus provides a synthesis of the available evidence-based scientific information, in the context of a significant and systematic international review, that is likely to be useful to governments and public health providers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945418     DOI: 10.1016/j.vaccine.2008.06.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Mapping HPV Vaccination and Cervical Cancer Screening Practice in the Pacific Region-Strengthening National and Regional Cervical Cancer Prevention.

Authors:  J Obel; J McKenzie; L E Buenconsejo-Lum; A M Durand; A Ekeroma; Y Souares; D Hoy; W Baravilala; S M Garland; S K Kjaer; A Roth
Journal:  Asian Pac J Cancer Prev       Date:  2015

2.  Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.

Authors:  Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson
Journal:  Int J Cancer       Date:  2012-01-27       Impact factor: 7.396

Review 3.  Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Authors:  Susanna Esposito; Paolo Bonanni; Stefania Maggi; Litjan Tan; Filippo Ansaldi; Pier Luigi Lopalco; Ron Dagan; Jean-Pierre Michel; Pierre van Damme; Jacques Gaillat; Roman Prymula; Timo Vesikari; Cristina Mussini; Uwe Frank; Albert Osterhaus; Lucia Pastore Celentano; Marta Rossi; Valentina Guercio; Gaetan Gavazzi
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

4.  Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay.

Authors:  Stephanie S Liu; Rebecca C Y Leung; Karen K L Chan; Annie N Y Cheung; Hextan Y S Ngan
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

5.  Awareness of cervical cancer prevention among mothers of adolescent daughters in Korea: qualitative research.

Authors:  Hae Won Kim; Duck Hee Kim
Journal:  BMJ Open       Date:  2015-05-14       Impact factor: 2.692

6.  Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies.

Authors:  Yu-qian Zhao; Irene J Chang; Fang-hui Zhao; Shang-ying Hu; Jennifer S Smith; Xun Zhang; Shu-min Li; Ping Bai; Wen-hua Zhang; You-lin Qiao
Journal:  BMC Cancer       Date:  2015-06-27       Impact factor: 4.430

7.  Genital human papillomavirus infection among women in Bangladesh: findings from a population-based survey.

Authors:  Quamrun Nahar; Farhana Sultana; Anadil Alam; Jessica Yasmine Islam; Mustafizur Rahman; Fatema Khatun; Nazmul Alam; Sushil Kanta Dasgupta; Lena Marions; Mohammed Kamal; Alejandro Cravioto; Laura Reichenbach
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

8.  A community-based intervention in middle schools to improve HPV vaccination and cervical cancer screening in Japan.

Authors:  Tomoko Ito; Remi Takenoshita; Keiichiro Narumoto; Melissa Plegue; Ananda Sen; Benjamin Franklin Crabtree; Michael Derwin Fetters
Journal:  Asia Pac Fam Med       Date:  2014-11-18

Review 9.  Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects.

Authors:  Jannah Wigle; Ernestina Coast; Deborah Watson-Jones
Journal:  Vaccine       Date:  2013-06-15       Impact factor: 3.641

10.  Over-Expressed miR-224 Promotes the Progression of Cervical Cancer via Targeting RASSF8.

Authors:  YongJie Huang; Yang Li; Fen F Wang; WeiGuo Lv; Xing Xie; Xiaodong Cheng
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.